T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum
T2 Biosystems (NASDAQ: TTOO), a leader in rapid detection of sepsis-causing pathogens, will participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:30 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
T2 Biosystems (NASDAQ: TTOO), a leader in rapid detection of sepsis-causing pathogens, will participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 2:30 PM ET. The presentation will be accessible via a live and recorded webcast on the company’s website.
The company is dedicated to enhancing patient care and lowering costs with innovative products like the T2Dx® Instrument and various diagnostic panels, driven by their proprietary T2 Magnetic Resonance (T2MR®) technology.
Details
News Market Reaction – TTOO
The recorded move for TTOO in the trading session of this news was -0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.
Management is scheduled to present Thursday, November 19, 2020 at 2:30pm ET. Interested parties may access a live and recorded webcast of the presentation on the “Investors” section of the Company’s website at www.t2biosystems.com.
About T2 Biosystems
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, the T2Bacteria® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Cauris™ Panel, and T2Lyme™ Panel, as well as additional products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers, and biothreat pathogens.
Media Contact:
Gina Kent, Vault Communications
gkent@vaultcommunications.com
610-455-2763
Investor Contact:
Philip Trip Taylor, Gilmartin Group
philip@gilmartinIR.com
415-937-5406
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.